

15. Organization WH. Obesity - Preventing and Managing the Global Epidemic: Report on a WHO Consultation. Geneva: World Health Organization; 2000. 266 s.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med*. 1985;13(10):818-29.
17. Jiménez D, García-Sánchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. *Chest*. 2021;159(3):1182-96.
18. Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano CA, Lugosi M, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. *Crit Care*. 2015;19(1):287.
19. Reis S, Faske A, Monsefi I, Langer F, Müller OJ, Kranke P, et al. Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis. *Thrombosis Research*. 2024;238:141-50.
20. Schulman S, Arnold DM, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, et al. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. *Journal of Thrombosis and Haemostasis*. 2024;22(6):1779-97.
21. van Roessel S, Middeldorp S, Cheung YW, Zwinderman AH, de Pont ACJM. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. *Neth J Med*. 2014;72(6):305-10.
22. Ratano D, Alberio L, Delodder F, Faouzi M, Berger MM. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. *Thrombosis Research*. 2019;175:53-8.
23. Trunfio M, Salvador E, Cabodi D, Marinaro L, Alcantarini C, Gaviraghi A, et al. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. *Thrombosis Research*. 2020;196:432-4.
24. De Schryver N, Serck N, Eeckhoudt S, Laterre PF, Wittebole X, Gérard L. Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial. *Journal of Critical Care*. 2022;70:154029.
25. Durila M, Vajter J, Garaj M, Berousek J, Lischke R, Hlavacek M, et al. Intravenous enoxaparin guided by anti-Xa in venovenous extracorporeal membrane oxygenation: A retrospective, single-center study. *Artificial Organs*. 2025;49(3):486-96.
26. Fiamoli V, Blatny J, Zapletal O, Kohlerova S, Janousova E. Treatment of Deep Vein Thrombosis with Continuous IV Infusion of LMWH: A Retrospective Study in 32 Children. *Thrombosis*. 2011;2011:1-4.
27. The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med*. 2021;385(9):777-89.
28. Queensland Health. Anticoagulant Guideline for Hospitalised Adult Patients - Last minor update March 2025 [Internet]. State of Queensland; 2025 [cit. 2025-12-20]. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0015/1152213/statewide-anticoagulant-guideline.pdf.
29. Duranteau J, Taccone FS, Verhamme P, Ageno W. European guidelines on perioperative venous thromboembolism prophylaxis: Intensive care. *European Journal of Anaesthesiology*. 2018;35(2):142-6.